Diaryl ureas for diseases mediated by PDGFR

A method for treating a disease or condition in mammal, or a mammalian cell thereof, which is a tumor, chronic myeloid leukemia, inflammation, renal disease, diabetic nephropathy, mesangial proliferative glomerulonephritis, atherosclerosis, restenosis, hypertension-related arterosclerosis, venous bypass graft arterosclerosis, scleroderma, interstitial pulmonary disease, a synovial disorder, arthritis, leukemia or lymphoma mediated by platelet-derived growth factor receptor-beta, where a defect in the receptor itself is involved in “causing” the disease;

• or functional activity of PDGFR results in the disease symptom and/or phenotype when inappropriately expressed,
• said method comprising:
• administering to a subject in need thereof, an effective amount of an aryl urea compound of formula I, a salt form of a compound of Formula I, an isolated or mixed stereoisomer of a compound of Formula I,
• wherein:
• A is phenyl, optionally substituted 1, 2 or 3 times by R3, wherein each R3 is independently C1-C5 alkyl, C1-C5 haloalkyl, up to per-haloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, up to per-haloalkoxy, halogen, cyano, or nitro;
• or A is a group of the formula:
• optionally substituted 1, 2, 3, 4, 5 or 6 times with R4 wherein each R4 is independently C1-C5 alkyl or halogen;
• B is phenylene, optionally substituted 1, 2 or 3 times by R2, or naphthylene, optionally substituted optionally substituted 1, 2 or 3 times by R2, wherein each R2 is independently C1-C5 alkyl, C1-C5 haloalkyl, up to per-haloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy up to per-haloalkoxyl, halogen, cyano or nitro;
• Q is cyano, —C(O)—Ra, or —C(O)—NRbRc, where each Ra, Rb and Rc is independently H or C1-C5 alkyl,
• L is —O— or —S—,
• m is an integer 0, 1, 2 or 3, and
• each R1 is independently halogen, C1-5 alkyl, C1-5 haloalkyl, up to per-haloalkyl, C1-5 alkoxy, C1-5 haloalkoxy, up to per-haloalkoxy, N-oxo or N-hydroxy.